CN1531954A - 一种治疗抑郁症的药物及其制备方法 - Google Patents
一种治疗抑郁症的药物及其制备方法 Download PDFInfo
- Publication number
- CN1531954A CN1531954A CNA031174841A CN03117484A CN1531954A CN 1531954 A CN1531954 A CN 1531954A CN A031174841 A CNA031174841 A CN A031174841A CN 03117484 A CN03117484 A CN 03117484A CN 1531954 A CN1531954 A CN 1531954A
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- depression
- present
- caulis acanthopanacis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 82
- 229940079593 drug Drugs 0.000 title claims description 14
- 238000000034 method Methods 0.000 title claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 208000020401 Depressive disease Diseases 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- -1 each reflux Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 244000141009 Hypericum perforatum Species 0.000 abstract 1
- 235000017309 Hypericum perforatum Nutrition 0.000 abstract 1
- 230000002898 effect on depression Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 241000581650 Ivesia Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000001430 anti-depressive effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 6
- 229960004801 imipramine Drugs 0.000 description 6
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 5
- 208000004130 Blepharoptosis Diseases 0.000 description 4
- 206010015995 Eyelid ptosis Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 201000003004 ptosis Diseases 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000000891 anti-reserpine Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03117484 CN1273150C (zh) | 2003-03-19 | 2003-03-19 | 一种治疗抑郁症的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03117484 CN1273150C (zh) | 2003-03-19 | 2003-03-19 | 一种治疗抑郁症的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1531954A true CN1531954A (zh) | 2004-09-29 |
CN1273150C CN1273150C (zh) | 2006-09-06 |
Family
ID=34284737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03117484 Expired - Lifetime CN1273150C (zh) | 2003-03-19 | 2003-03-19 | 一种治疗抑郁症的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1273150C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104055812A (zh) * | 2014-03-13 | 2014-09-24 | 江苏康缘药业股份有限公司 | 一种具有抗抑郁作用的组合物以及制备方法与用途 |
CN108283674A (zh) * | 2018-03-06 | 2018-07-17 | 深圳市蓝能健康科技有限公司 | 用于治疗调节抑郁症的药品及配制该药品的制品 |
CN112741887A (zh) * | 2019-10-30 | 2021-05-04 | 唐启盛 | 一种治疗抑郁症的中药组合物 |
-
2003
- 2003-03-19 CN CN 03117484 patent/CN1273150C/zh not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104055812A (zh) * | 2014-03-13 | 2014-09-24 | 江苏康缘药业股份有限公司 | 一种具有抗抑郁作用的组合物以及制备方法与用途 |
CN104055812B (zh) * | 2014-03-13 | 2017-07-21 | 江苏康缘药业股份有限公司 | 一种具有抗抑郁作用的组合物以及制备方法与用途 |
CN108283674A (zh) * | 2018-03-06 | 2018-07-17 | 深圳市蓝能健康科技有限公司 | 用于治疗调节抑郁症的药品及配制该药品的制品 |
CN112741887A (zh) * | 2019-10-30 | 2021-05-04 | 唐启盛 | 一种治疗抑郁症的中药组合物 |
CN112741887B (zh) * | 2019-10-30 | 2022-02-18 | 唐启盛 | 一种治疗抑郁症的中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1273150C (zh) | 2006-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1250255C (zh) | 治疗肠功能紊乱疾病的中药组合物及其制剂 | |
CN100337651C (zh) | 一种预防禽流感的中药组合物及其制备方法和应用 | |
CN1199656C (zh) | 一种治疗重症肌无力的药物 | |
CN1283281C (zh) | 一种含酸枣仁、灵芝、人参叶药物组合物及其制备和应用 | |
CN1531954A (zh) | 一种治疗抑郁症的药物及其制备方法 | |
CN1723936A (zh) | 一种抗抑郁症的中药及其制备方法 | |
CN100341540C (zh) | 独活寄生颗粒及其制备方法 | |
CN1733286A (zh) | 一种防治酒精性肠道损伤和肝损伤的中药复方制剂 | |
CN1634479A (zh) | 一种治疗感冒及上呼吸道感染的药物组合物、其制备方法及其用途 | |
CN1872186A (zh) | 复方枣仁胶囊及其制备方法 | |
CN1628770A (zh) | 一种止咳平喘的药物及其制备方法 | |
CN1276758C (zh) | 治疗慢性疲劳综合症的中药复方制剂及其制备工艺 | |
CN1183946C (zh) | 一种治疗抑郁症的药物及其制备方法 | |
CN1308017C (zh) | 一种治疗泻泄、痢疾和痧气的药物组合物 | |
CN1471914A (zh) | 防治由sars病毒引起的非典型肺炎的药物和应用及其制备方法 | |
CN1291103A (zh) | 预防与治疗爱滋病的草药组合物 | |
CN1562145A (zh) | 广升麻提取物、其制备方法及其用途 | |
CN1579441A (zh) | 止咳药物及其制备方法 | |
CN1209158C (zh) | 一种治疗小儿病毒性肺炎的清肺口服液制剂及其制备方法 | |
CN1651034A (zh) | 一种用于治疗肝病的参柴肝康滴丸及其制备方法 | |
CN1275591C (zh) | 一种治疗心血管疾病的中药缓释剂及其制备方法 | |
CN1709329A (zh) | 一种治疗女性痛经的组合物及制备方法 | |
CN1772268A (zh) | 一种提高免疫力的药物组合物及其制备方法和应用 | |
CN1895324A (zh) | 一种金感敏分散片及其制备方法 | |
CN1853711A (zh) | 一种心脉康中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDU KANGHONG MEDICINE GROUP CO.LTD. Free format text: FORMER OWNER: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO., LTD. Effective date: 20080912 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080912 Address after: No 36, Shu West Road, Chengdu, Sichuan, Jinniu District Patentee after: CHENGDU KANGHONG PHARMACEUTICAL Co.,Ltd. Address before: No. 36 Shu West Road, Sichuan, Jinniu District Patentee before: Chengdu Kanghong technology industry (Group) Co.,Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20040929 Assignee: Sichuan Jishengtang Pharmaceutical Co.,Ltd. Assignor: CHENGDU KANGHONG PHARMACEUTICAL Co.,Ltd. Contract record no.: 2017510000031 Denomination of invention: Medicine for treating depression and its preparing method Granted publication date: 20060906 License type: Common License Record date: 20171018 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201021 Address after: Pengzhou City, Chengdu City, Sichuan province 611930 days Peng Zhen Hua Long Road No. 89 Patentee after: Sichuan Jishengtang Pharmaceutical Co.,Ltd. Address before: 610036 Jinniu District, Sichuan, Sichuan West Road, No. 36, No. Patentee before: CHENGDU KANGHONG PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20060906 |
|
CX01 | Expiry of patent term |